Supercharge Your Innovation With Domain-Expert AI Agents!

Medicament composition

A composition and drug technology, applied in the field of medicine, can solve the problems of no effective ingredient research, no research on the formulation of salvianolic acid A prescription, no research on prescription formulation, etc.

Inactive Publication Date: 2008-11-12
PHARMA RES INST OF BENCAO TIANYUAN OF BEIJING
View PDF0 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Salvia miltiorrhiza is the root and rhizome of Salvia miltiorrhiza Bge. It is slightly cold in nature and bitter in taste. Chest and abdomen tingling pain, heat arthralgia pain, sore swelling and pain, hepatosplenomegaly, angina pectoris and other symptoms are commonly used medicinal flavors in traditional Chinese medicine for promoting blood circulation and removing blood stasis; studies have shown that the main active ingredient in Salvia miltiorrhiza is salvianolic acid A (Du Guanhua [Basic Medicine] and Clinical, 2000, 20(5): 10-14], Hu Yiyang [Acta Pharmacology of Traditional Chinese Medicine, 1997, 18(5): 478-480]), but because of the defects of the existing technology, it is impossible to obtain batch-level salvianolic acid A, mainly because the content of salvianolic acid A in Salvia miltiorrhiza is very low, only about 5 / 10,000. Even if it is extracted through a series of processes, only trace amounts of salvianolic acid A can be obtained. Therefore, it is impossible to extract Salvianolic acid A and other active parts or active ingredients of traditional Chinese medicines have been researched on the formulation of prescriptions. Although Danshen Salvianolic Acid has participated in the research on the compatibility of other traditional Chinese medicines, the main research focus is still on the formulation of salvianolic acid B. This kind of research has a certain effect, but the most effective ingredients in traditional Chinese medicine have not been studied, so it is impossible to achieve a superior effect;
[0006] Check the literature and patents, but there is no report on the study of formula formulation of salvianolic acid A

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicament composition
  • Medicament composition
  • Medicament composition

Examples

Experimental program
Comparison scheme
Effect test

experiment approach 1

[0101] Scheme 1: 0.2 parts by weight of salvianolic acid A;

[0102] Scheme 2: 0.4 parts by weight of salvianolic acid A;

[0103] Scheme 3: 0.6 parts by weight of salvianolic acid A;

[0104] Scheme 4: 0.8 parts by weight of salvianolic acid A;

[0105] Scheme 5: 1 part by weight of salvianolic acid A;

[0106] Scheme 6: 2 parts by weight of salvianolic acid A;

[0107]Experimental method: Experimental method: take healthy SD rats, weighing 240-260g, and randomly divide them into blank control group and experimental scheme group. Placed in the same environment for pre-feeding for 2 days, free to eat and drink. After the pre-breeding, carry out the experiment, weigh the animals, inject 20% urethane at 0.6ml / 100g intraperitoneally, after the anesthesia is satisfactory, fix it on the mouse board in a supine position, intubate the trachea, connect the ventilator, and use a tidal volume of 10-12ml , The frequency of 70 times / min is given to exhale, continuous positive press...

experiment approach 2

[0111] Scheme 1: 1 part by weight of American ginsenoside;

[0112] Scheme 2: 5 parts by weight of American ginseng saponins;

[0113] Scheme 3: 10 parts by weight of American ginseng saponins;

[0114] Scheme 4: 20 parts by weight of American ginseng saponins;

[0115] Scheme 5: 30 parts by weight of American ginseng saponins;

[0116] Scheme 6: 40 parts by weight of American ginseng saponins;

[0117] Scheme 7: 50 parts by weight of American ginseng saponins;

[0118] Experimental method: Carry out according to the above-mentioned experimental method, and the experimental results are shown in Table 9:

[0119] Table 8 Experimental results of different schemes of salvianolic acid A

[0120]

[0121] Table 9 Experimental results of different schemes of American ginseng saponins

[0122]

[0123] Note: The above experimental scheme was administered by intragastric administration, and the experimental results were similar to the above experimental results.

[0124] ...

Embodiment 1

[0290] Preparation of salvianolic acid A:

[0291] Extract the salvia miltiorrhiza with 70% ethanol solution to obtain the alcohol extract, concentrate the ethanol to the utmost, adjust the pH value to 4.5, 120°C temperature, and a gauge pressure of 0.10MPa, and heat for 4 hours; the solution is filtered, and the filtrate is passed through HPD-450 Pore ​​resin column chromatography separation, first eluted with water and 20% dilute ethanol to remove impurities, then eluted with 50% ethanol, collected the eluate, concentrated, and dried to obtain salvianolic acid A with a content of 53.8% .

[0292] or

[0293]Extract the salvia miltiorrhiza with 60% ethanol solution to obtain the alcohol extract, concentrate the ethanol to the maximum, adjust the pH value to 4.0, 125°C temperature, and a gauge pressure of 0.14MPa, and heat for 2 hours; the solution is filtered, and the filtrate is passed through D101 macroporous resin Column chromatography separation, first eluted with water...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a medicine composition which is characterized in that: the medicine composition is determined through a dose-response relationship experiment, a harmacodynamic verification experiment, a pharmacokinetic experiment and a toxicological experiment, wherein, the medicine composition comprises the following compositions in portion by weight: 1 to 10 portions of salvianolic acid A from salvia miltiorrhiza, and 1 to 50 portions of blood-quickening and stasis-dispelling effective constituents of traditional Chinese medicines; or preferable 1 to 5 portions of the salvianolic acid A from salvia miltiorrhiza, and 20 to 50 portions of the blood-quickening and stasis-dispelling effective compositions of the traditional Chinese medicines; or preferable 6 to 10 portions of the salvianolic acid A from salvia miltiorrhiza, and 1 to 19 portions of the blood-quickening and stasis-dispelling effective compositions of the traditional Chinese medicines. As shown in a pharmacologic experiment of the composition, the medicine composition has good pharmacologic effect.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a pharmaceutical composition comprising salvianolic acid A and active ingredients of traditional Chinese medicines for promoting blood circulation and removing blood stasis; [0002] The active ingredients of traditional Chinese medicine for promoting blood circulation and removing blood stasis in this application refer to one or more of the following: notoginseng saponin, ligustrazine, angelica ligustilide or ferulic acid, paeoniflorin, timosaponin, gypenoside, muscone , eleutheroside, balsamic volatile oil, puerarin, ginkgolide, ginkgo flavonoids, jujube flavonoids, jujubeolin, amygdalin, paeonol, American ginsenoside, aescin or aescin sodium, epimedium Huoside; [0003] The active ingredients of the traditional Chinese medicine for promoting blood circulation and removing blood stasis are prepared according to existing literature or patented methods. Background technique ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61K31/704A61K31/7028A61K31/575A61K31/496A61K31/365A61K31/352A61K31/343A61K36/537A61K36/48A61K9/08A61K9/10A61K9/16A61K9/20A61K9/48A61P9/10A61K31/122
Inventor 顾群李志刚米长江栗艳彬林治荣金治刚渠守峰郭小鹏
Owner PHARMA RES INST OF BENCAO TIANYUAN OF BEIJING
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com